TrialThe Lancet. Oncology2018

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Roy S Herbst et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.